Sortis 80

Poland
Brand name Sortis 80
Form tablets, film-coated
Active substance / Dosage
Prescription type Prescription only
ATC code
Registration number 100452973
Manufacturer Upjohn EESV
Sortis 80 tablets, film-coated

Package leaflet: Information for the user

Warning! Keep this leaflet! Information on the immediate packaging is in a foreign language.
Sortis 80 (Lipitor), 80 mg, film-coated tablets
Atorvastatin
Sortis 80 and Lipitor are different trade names for the same medicine.
Please read the entire leaflet carefully before using the medicine, as it contains
important information for the patient.

  • Keep this leaflet, so that you can read it again if necessary.
  • If you have any doubts, please consult your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for a specific individual. Do not pass it on to others. The medicine may harm another person, even if their symptoms are identical.
  • If you experience any adverse effects, including any adverse effects not listed in this leaflet, inform your doctor, pharmacist, or nurse. See section 4.

Table of contents

  1. What Sortis 80 is and what it is used for
  2. What you need to know before taking Sortis 80
  3. How to take Sortis 80
  4. Possible side effects
  5. How to store Sortis 80
  6. Contents of the pack and other information

1. What Sortis 80 is and what it is used for

Sortis 80 belongs to a group of medicines called statins, which regulate lipid (fat) metabolism in the body.
Sortis 80 is used to reduce blood levels of lipids known as cholesterol and triglycerides when a low-fat diet and lifestyle changes alone are not effective. Sortis 80 may also be used to reduce the risk of heart disease, even when cholesterol levels are normal. A standard low-cholesterol diet should be continued during treatment.

2. Important information before using Sortis 80

When not to use Sortis 80:

  • if the patient is allergic to atorvastatin or any of the other ingredients of this medicine (listed in section 6),
  • if the patient currently has or has previously had liver disease,
  • if the patient has unexplained abnormal liver function test results,
  • in women of childbearing potential who are not using effective methods of contraception,
  • in pregnant women or women planning to become pregnant,
  • in breastfeeding women,
  • if the patient is taking glecaprevir with pibrentasvir for the treatment of hepatitis C virus infection.

Warnings and precautions
Before starting treatment with Sortis 80, discuss this with your doctor, pharmacist, or nurse:

  • if the patient has severe respiratory failure,
  • if the patient is taking or has taken fusidic acid orally or by injection within the last 7 days (a medicine used to treat bacterial infections). Concomitant use of fusidic acid with Sortis 80 may lead to serious muscle problems (rhabdomyolysis),
  • in case of haemorrhagic stroke, or if there is a small amount of fluid in the brain from a previous stroke,
  • in case of kidney problems,
  • in case of hypothyroidism,
  • in case of recurrent or unexplained muscle pain or muscle problems in the past, or similar problems in family members,
  • in case of muscle problems during previous treatment with other lipid-lowering medicines (e.g. other statins or fibrates),
  • in case of regular consumption of large amounts of alcohol,
  • in case of previous liver disease,
  • in patients over 70 years of age.

For patients with any of the above conditions, the doctor may order blood tests before starting treatment with Sortis 80 and, where possible, during treatment to monitor the risk of muscle-related adverse effects. It is known that the risk of muscle-related adverse effects, such as rhabdomyolysis, is higher when certain medicines are used concomitantly (see section 2 “Sortis 80 and other medicines”).
Inform your doctor or pharmacist if muscle weakness persists. Additional tests and possibly additional medicines may be necessary to diagnose and treat this condition.
While taking this medicine, your doctor will closely monitor you for the development of diabetes or risk of developing diabetes. Patients with high levels of blood sugar and fats, overweight patients, and those with high blood pressure may be at increased risk of developing diabetes.

Sortis 80 and other medicines
Tell your doctor or pharmacist about all medicines you are currently taking, have recently taken, or plan to take. Some medicines may alter the effect of Sortis 80 or their effect on the body may be altered by Sortis 80. This type of interaction may reduce the effectiveness of one or both medicines. It may also increase the risk of serious adverse effects, including severe muscle damage known as rhabdomyolysis, described in section 4:

  • immunosuppressive medicines, e.g. cyclosporine,
  • certain antibiotics or antifungal medicines, e.g. erythromycin, clarithromycin, telithromycin, ketoconazole, itraconazole, voriconazole, fluconazole, posaconazole, rifampicin, fusidic acid,
  • other lipid-regulating medicines, e.g. gemfibrozil, other fibrates, colestipol,
  • certain calcium channel blockers used for angina or hypertension, e.g. amlodipine, diltiazem; and medicines regulating heart rhythm, e.g. digoxin, verapamil, amiodarone,
  • letermovir, a medicine used to prevent cytomegalovirus disease,
  • medicines used to treat HIV infection, e.g. ritonavir, lopinavir, atazanavir, indinavir, darunavir, tipranavir in combination with ritonavir, etc.,
  • certain medicines used to treat hepatitis C virus infection, e.g. telaprevir, boceprevir, and combination medicines containing elbasvir with grazoprevir, ledipasvir with sofosbuvir,
  • other medicines known to interact with Sortis 80 include ezetimibe (which reduces cholesterol levels), warfarin (which reduces blood clotting), oral contraceptives, stiripentol (an anticonvulsant used to treat epilepsy), cimetidine (used to treat heartburn and stomach ulcers), phenazone (a painkiller),
  • colchicine (a medicine used to treat gout), and antacids (medicines used for indigestion containing aluminium or magnesium),
  • over-the-counter medicines: St John’s wort (Hypericum perforatum),
  • if the patient needs to take oral fusidic acid to treat a bacterial infection, treatment with this medicine should be temporarily discontinued. The doctor will inform the patient when it is safe to restart treatment with Sortis 80. Taking Sortis 80 together with fusidic acid may rarely lead to muscle weakness, tenderness, or pain (rhabdomyolysis). More information about rhabdomyolysis can be found in section 4.

Sortis 80 with food, drink, and alcohol
Information on the use of Sortis 80 can be found in section 3. However, please note the following: Grapefruit juice
Do not consume more than one or two small glasses of grapefruit juice per day, as larger quantities may alter the effect of Sortis 80. Alcohol
While taking this medicine, avoid consuming excessive amounts of alcohol. More detailed information on this is provided in section 2 “Warnings and precautions”.

Pregnancy and breastfeeding
The use of Sortis 80 in women who are pregnant or planning to become pregnant is contraindicated.
The use of Sortis 80 in women of childbearing potential is contraindicated if they are not using effective methods of contraception.
The use of Sortis 80 during breastfeeding is contraindicated.
The safety of using Sortis 80 during pregnancy and breastfeeding has not been established.
Before taking any medicine, consult your doctor or pharmacist.

Driving and using machines
Generally, this medicine does not affect the ability to drive or operate machinery. However, patients should not drive if this medicine affects their ability to do so. Do not use tools or machines if taking this medicine affects your ability to operate them.

Sortis 80 contains lactose monohydrate
Patients who have been advised by their doctor that they have an intolerance to certain sugars should consult their doctor before taking this medicine.

Sortis 80 contains sodium
This medicine contains less than 1 mmol (23 mg) of sodium per tablet, meaning the medicine is considered "sodium-free".

Sortis 80 contains benzoic acid (E 210)
This medicine contains 0.00032 mg of benzoic acid per tablet.

3. How to use Sortis 80

Before starting treatment, your doctor will recommend a low-cholesterol diet; this diet should be continued during treatment with Sortis 80.
Available on the market are: Sortis 10 (10 mg), Sortis 20 (20 mg), Sortis 40 (40 mg), and Sortis 80 (80 mg).
The usual starting dose of Sortis for adults and children aged 10 years or older is 10 mg once daily. If necessary, your doctor may increase this dose up to the dose appropriate for the patient. Your doctor will adjust the dose at intervals of at least 4 weeks. The maximum dose of Sortis is 80 mg once daily.
Sortis 80 tablets should be swallowed whole with water; they may be taken at any time of day, with or without food. However, it is advisable to take the tablet at approximately the same time each day.
This medicine should always be used exactly as prescribed by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist.
The duration of treatment with Sortis 80 is determined by the doctor.
If you feel that the effect of Sortis 80 is too strong or too weak, consult your doctor.
Taking more Sortis 80 than prescribed
If you accidentally take too many Sortis 80 tablets (more than the usual daily dose), contact your doctor or the nearest hospital for advice.
Missing a dose of Sortis 80
If you forget to take your dose, simply take the next dose at the scheduled time. Do not take a double dose to make up for a missed dose.
Stopping treatment with Sortis 80
If you have any further questions about the use of this medicine, consult your doctor or pharmacist.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone will experience them.
If the patient experiences any of the serious adverse reactions or symptoms listed below, they should
stop taking the medicine immediately and contact their doctor or go to the emergency department of
the nearest hospital.

Rare: may occur in no more than 1 in 1,000 people

  • Severe allergic reaction causing swelling of the face, tongue, and throat, which may lead to severe breathing difficulties.
  • Severe illness characterized by skin peeling and swelling, skin blisters, and sores in the mouth, eyes, genitals, accompanied by fever. Skin rash with pink-red spots, especially on the palms or soles, possibly with blisters.
  • Muscle weakness, tenderness, muscle pain, or muscle rupture, or red-brown discoloration of urine. If these symptoms occur together with malaise or high fever, this may indicate rhabdomyolysis (breakdown of skeletal muscle). Rhabdomyolysis does not always resolve even after discontinuation of atorvastatin, may be life-threatening, and can lead to kidney problems.

Very rare: may occur in no more than 1 in 10,000 people

  • Unexpected or unusual bleeding or bruising, which may indicate liver abnormalities. Medical advice should be sought as soon as possible.
  • Lupus-like syndrome (including rash, joint disorders, and effects on blood cells).

Other possible adverse reactions of Sortis 80 medicine:
Common: may occur in no more than 1 in 10 people

  • Nasal inflammation, sore throat, nosebleeds
  • Allergic reactions
  • Increased blood glucose levels (in patients with diabetes, blood glucose levels should continue to be carefully monitored), increased blood creatine kinase levels
  • Headache
  • Nausea, constipation, bloating, indigestion, diarrhea
  • Joint pain, muscle pain, and back pain
  • Blood test results indicating abnormal liver function.

Uncommon: may occur in no more than 1 in 100 people

  • Anorexia (loss of appetite), weight gain, decreased blood glucose levels (in patients with diabetes, blood glucose levels should continue to be carefully monitored)
  • Nightmares, insomnia
  • Dizziness, numbness or tingling in fingers, hands, and feet, reduced sensitivity to pain and touch, altered taste, memory loss
  • Blurred vision
  • Ringing in the ears and (or) in the head
  • Vomiting, regurgitation, pain in the upper and lower abdomen, pancreatitis (causing abdominal pain)
  • Hepatitis
  • Rash, skin rash and itching, urticaria, hair loss
  • Neck pain, muscle fatigue
  • Fatigue, malaise, weakness, chest pain, swelling, especially in the ankles, elevated temperature
  • Presence of white blood cells in urine analysis.

Rare: may occur in no more than 1 in 1,000 people

  • Vision disorders
  • Unexpected bleeding or bruising (bruises)
  • Cholestasis (yellowing of the skin and whites of the eyes)
  • Tendon rupture.

Very rare: may occur in no more than 1 in 10,000 people

  • Allergic reactions – symptoms may include sudden shortness of breath and chest pain or tightness, eyelid, facial, lip, oral cavity, tongue or throat swelling, breathing difficulties, collapse
  • Hearing loss
  • Gynaecomastia (excessive growth of glandular breast tissue in men).

Frequency unknown: frequency cannot be estimated from available data

  • Persistent muscle weakness.

Other possible adverse reactions reported during treatment with some statins (medicines of the same type):

  • Sexual dysfunction
  • Depression
  • Breathing problems, including persistent cough and (or) shortness of breath or fever
  • Diabetes; the likelihood of developing this condition is higher in patients with high blood sugar and fat levels, overweight patients, and those with high blood pressure. During treatment with this medicine, the doctor will perform appropriate tests in the patient.

Reporting of adverse reactions
If any adverse reactions occur, including any possible adverse reactions not listed in this leaflet, inform your doctor, pharmacist, or nurse. Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, phone: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Reporting adverse reactions helps to provide more information on the safety of the medicine.

5. How to store Sortis 80

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the container. The expiry date refers to the last day of the specified month.
No special storage conditions apply.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. Such measures help protect the environment.

6. Contents of the pack and other information

What Sortis 80 contains

  • The active substance is atorvastatin. Each coated tablet contains 80 mg of atorvastatin (as atorvastatin calcium trihydrate).
  • The other ingredients are: calcium carbonate, microcrystalline cellulose, lactose monohydrate, sodium croscarmellose, polysorbate 80, hydroxypropylcellulose, and magnesium stearate.

The coating of Sortis 80 contains: hypromellose, macrogol 8000, titanium dioxide (E 171), talc,
simethicone emulsion containing simethicone, emulsifying stearates (polysorbate 65, polyethylene glycol 400 stearate, glycerol monostearate 40-55), thickening agents (methylcellulose, xanthan gum), benzoic acid (E 210), sorbic acid, and sulfuric acid.

What Sortis 80 looks like and contents of the pack
White, round, film-coated tablets with a diameter of 11.9 mm, embossed with "80" on one side and "ATV" on the other side.
Sortis 80 is available in blisters made of PA/Al/PVC//Al/vinyl foil containing 28 film-coated tablets, packed in a cardboard carton.

For more detailed information, please contact the responsible party or the parallel importer.

Marketing Authorisation Holder in Ireland, country of export:
Upjohn EESV
Rivium Westlaan 142
2909 LD Capelle aan den IJssel, The Netherlands

Manufacturer:
Pfizer Manufacturing Deutschland GmbH
Betriebsstätte Freiburg
Mooswaldallee 1, 79090 Freiburg, Germany
Mylan Hungary Kft.
Mylan utca 1, Komárom 2900, Hungary

Parallel Importer:
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw, Poland

Repackaged by:
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw, Poland

Marketing Authorisation Number in Ireland, country of export: PA 23055/017/004
Parallel Import Licence Number: 198/21

Translation of the abbreviations for days of the week printed on each tablet in the immediate packaging:
MON – Monday, TUE – Tuesday, WED – Wednesday, THUR – Thursday, FRI – Friday,
SAT – Saturday, SUN – Sunday.